What Happened
Retatrutide's TRIUMPH-2 study emerged as a headline result in the lead-up to the EASD 2026 annual meeting. In the phase 3 study, adults with obesity or overweight plus type 2 diabetes lost up to an average of about 20.8% of body weight, roughly 22.5 kg or 49.6 lb, and lowered A1C by up to about 1.6% at 80 weeks. The data were slated for presentation at EASD 2026 in Milan, held September 28 to October 2, placing them before a large scientific audience during a period dense with GLP-1 research.
What Retatrutide Is
Retatrutide is Eli Lilly's triple agonist, activating the GLP-1, GIP, and glucagon receptors. That triple mechanism has been associated with some of the strongest weight-loss figures in the field. TRIUMPH-2 extends the evidence into a specific and important population: people who have type 2 diabetes alongside obesity or overweight, a group in which metabolic management is often more complex.
The TRIUMPH-2 Numbers
In TRIUMPH-2, the results at 80 weeks were substantial on two fronts. Weight loss reached up to an average of about 20.8%, equivalent to roughly 22.5 kg or 49.6 lb. A1C, the standard measure of long-term blood-glucose control, fell by up to about 1.6%. The dual benefit matters in this population because type 2 diabetes management involves both weight and glucose control, and a compound moving both is of particular interest to researchers studying the condition.
It is worth noting that weight loss in people with type 2 diabetes has often been somewhat lower than in obesity populations without diabetes, a pattern seen across the GLP-1 field. That context makes the TRIUMPH-2 figures notable, since they were achieved in a population where the metabolic response to these agents has tended to be more modest.
The Broader TRIUMPH Program
TRIUMPH-2 is part of a larger program. TRIUMPH-1, in a different population, showed up to about 30.3% weight loss, one of the higher figures reported across the obesity field. Together, the TRIUMPH studies build a picture of retatrutide's effects across populations, from those with diabetes to those without, allowing comparisons of how the compound performs when the underlying metabolic profile differs. That breadth is part of what has made retatrutide one of the most closely followed compounds in development.
The data were positioned for presentation at the EASD 2026 annual meeting in Milan, running September 28 to October 2. EASD, the European Association for the Study of Diabetes, is a major venue where metabolic-disease research is presented and scrutinized by the field. Slotting TRIUMPH-2 into that meeting placed it before a large scientific audience during a stretch of the calendar crowded with GLP-1 data, ensuring the results received prominent attention and independent examination.
What It Means
TRIUMPH-2 reinforces retatrutide's profile as a high-efficacy triple agonist, now with detailed evidence in the type 2 diabetes and obesity population. As part of the broader TRIUMPH program, it contributes to a body of data that has made retatrutide one of the most watched compounds heading into the field's major 2026 scientific meeting, and it sharpens the comparison between triple-agonist and other mechanisms in patients with diabetes.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.